BRCA Share: A Collection of Clinical BRCA Gene Variants

As next‐generation sequencing increases access to human genetic variation, the challenge of determining clinical significance of variants becomes ever more acute. Germline variants in the BRCA1 and BRCA2 genes can confer substantial lifetime risk of breast and ovarian cancer. Assessment of variant pathogenicity is a vital part of clinical genetic testing for these genes. A database of clinical observations of BRCA variants is a critical resource in that process. This article describes BRCA Share™, a database created by a unique international alliance of academic centers and commercial testing laboratories. By integrating the content of the Universal Mutation Database generated by the French Unicancer Genetic Group with the testing results of two large commercial laboratories, Quest Diagnostics and Laboratory Corporation of America (LabCorp), BRCA Share™ has assembled one of the largest publicly accessible collections of BRCA variants currently available. Although access is available to academic researchers without charge, commercial participants in the project are required to pay a support fee and contribute their data. The fees fund the ongoing curation effort, as well as planned experiments to functionally characterize variants of uncertain significance. BRCA Share™ databases can therefore be considered as models of successful data sharing between private companies and the academic world.

[1]  V Shane Pankratz,et al.  Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Jay Shendure,et al.  Saturation Editing of Genomic Regions by Multiplex Homology-Directed Repair , 2014, Nature.

[3]  Matthew S. Lebo,et al.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.

[4]  Erika Check Hayden,et al.  Funding for model-organism databases in trouble , 2016 .

[5]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[6]  F. Couch,et al.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.

[7]  H. Ostrer,et al.  Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway. , 2015, Human molecular genetics.

[8]  Csilla Szabo,et al.  The Breast Cancer Information Core: Database design, structure, and scope , 2000, Human mutation.

[9]  R. Quatrano.  Genomics , 1998, Plant Cell.

[10]  Orion J. Buske,et al.  The Matchmaker Exchange: A Platform for Rare Disease Gene Discovery , 2015, Human mutation.

[11]  Thierry Soussi,et al.  UMD (Universal Mutation Database): 2005 update , 2005, Human mutation.

[12]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[13]  Sue Healey,et al.  ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.

[14]  A. Fabre,et al.  Design of a Core Classification Process for DNA Mismatch Repair Variations of A Priori Unknown Functional Significance , 2013, Human mutation.

[15]  D. Hedley,et al.  Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Etienne Rouleau,et al.  A guide for functional analysis of BRCA1 variants of uncertain significance , 2012, Human mutation.

[17]  G. Llort,et al.  SEOM clinical guidelines for hereditary cancer , 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[18]  F. Couch,et al.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  F. Couch,et al.  Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? , 2007, Breast Cancer Research.

[20]  D. Evans,et al.  Genetic testing for familial/hereditary breast cancer—comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany , 2011, Journal of Community Genetics.

[21]  David L. Young,et al.  Massively Parallel Functional Analysis of BRCA1 RING Domain Variants , 2015, Genetics.

[22]  R. Henrique,et al.  Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families. , 2014, The Journal of molecular diagnostics : JMD.

[23]  F. Couch,et al.  Functional Assays for Analysis of Variants of Uncertain Significance in BRCA2 , 2014, Human mutation.

[24]  Douglas F Easton,et al.  Genetic evidence and integration of various data sources for classifying uncertain variants into a single model , 2008, Human mutation.

[25]  Jocelyn Kaiser,et al.  BIOMEDICAL RESOURCES. Funding for key data resources in jeopardy. , 2016, Science.

[26]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[27]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[28]  Etienne Rouleau,et al.  Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases , 2011, Nucleic Acids Res..

[29]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[30]  P. Maillet,et al.  BRCA1 and BRCA2 Unclassified Variants and Missense Polymorphisms in Algerian Breast/Ovarian Cancer Families , 2012, Disease markers.

[31]  Kara Dolinski,et al.  An extended set of yeast-based functional assays accurately identifies human disease mutations , 2016, Genome research.

[32]  Peter Bouwman,et al.  A high-throughput functional complementation assay for classification of BRCA1 missense variants. , 2013, Cancer discovery.

[33]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[34]  Euan A Ashley,et al.  Clinical interpretation and implications of whole-genome sequencing. , 2014, JAMA.

[35]  W. Burke,et al.  Genetic Testing , 2019, Definitions.

[36]  Orli G. Bahcall.  Genetic testing: ACMG guides on the interpretation of sequence variants , 2015, Nature Reviews Genetics.

[37]  E. Schröck,et al.  Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium , 2013, Journal of Medical Genetics.

[38]  Raymond M. Moore,et al.  Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. , 2016, American journal of human genetics.

[39]  Ourania Horaitis,et al.  Time for a unified system of mutation description and reporting: a review of locus-specific mutation databases. , 2002, Genome research.

[40]  Richard J. Wenstrup,et al.  Comparison of locus-specific databases for BRCA1 and BRCA2 variants reveals disparity in variant classification within and among databases , 2015, Journal of Community Genetics.

[41]  Raymond Dalgleish,et al.  HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.

[42]  Kee Seng Chia,et al.  Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women , 2012, Breast Cancer Research.

[43]  Avni Santani,et al.  Actionable exomic incidental findings in 6503 participants: challenges of variant classification , 2015, Genome research.

[44]  Rachel G Liao,et al.  A federated ecosystem for sharing genomic, clinical data , 2016, Science.

[45]  Jeroen F. J. Laros,et al.  LOVD v.2.0: the next generation in gene variant databases , 2011, Human mutation.

[46]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[47]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[48]  Emily H Turner,et al.  Actionable, pathogenic incidental findings in 1,000 participants' exomes. , 2013, American journal of human genetics.

[49]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[50]  Giovanni Parmigiani,et al.  Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO , 2015, Cancer informatics.

[51]  Christophe Béroud,et al.  UMD‐Predictor: A High‐Throughput Sequencing Compliant System for Pathogenicity Prediction of any Human cDNA Substitution , 2016, Human mutation.

[52]  Dominique Vaur,et al.  Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes , 2011, European Journal of Human Genetics.